Curis reports third-quarter loss and advances emavusertib studies
Curis reported its third-quarter 2026 results on November 12, posting a net loss of $8.1 million, or $1.94 per basic and diluted share, with no quarterly revenue. The company said 12 patients were enrolled in its CLL study and that initial data are expected in December 2026. Curis also said financing completed in August 2026 and October 2026 should extend its operating cash runway into 2027.
Why it matters
The results show continued losses and no current-quarter revenue, while the clinical programs remain the main potential value driver. Curis expects its available cash, together with October financing, to fund existing operations into 2027, and management is targeting potential accelerated approval submissions in 2027.
Key facts
- 1Curis recorded a third-quarter 2026 net loss of $8.1 million, equal to $1.94 per share on both a basic and diluted basis. prnewswire.com
- 2The company reported no revenue for the quarter ended September 30, 2026. prnewswire.com
- 3The TakeAim CLL study had enrolled 12 patients, with initial results expected in December 2026. prnewswire.com
- 4Curis held $5 million in cash and cash equivalents as of September 30, 2026. finance.yahoo.com
- 5Curis said its cash and October financing should fund existing operations into '27 under its current operating plan. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.